Post by
allibabba on Mar 19, 2024 12:46pm
For what it’s worth
I think that this company will eventually gain some traction selling API and may someday be a partner in producing a generic drug. I believe that it may eventually get 25ish million a quarter in revenue. With a cash flow positive and fair P/E I see this as a .50 stock in the medium term.
Comment by
okgonow on Mar 19, 2024 12:51pm
nope if we are talking canabis/CBD based drugs then i would direct you to JAZZ Pharmasuticals who developed and produce EPIDIOLEX the holy grail everyone is trying to emulate they hold all patenets as far as the drug goes thats why theyv are making money hand over fist!!! none of the drugs and trials we are involved with are LABS property we are just supplying the CBD in the formulations.